Genmab A/S (GMAB)
51.15
-0.20
(-0.39%)
USD |
NASDAQ |
Nov 20, 10:35
Genmab Cash from Operations (Quarterly) : 520.21M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 520.21M |
| June 30, 2026 | 51.04M |
| March 31, 2026 | 3.011M |
| December 31, 2025 | 301.02M |
| September 30, 2025 | 536.82M |
| June 30, 2025 | 64.59M |
| March 31, 2025 | 287.20M |
| December 31, 2024 | 398.22M |
| September 30, 2024 | 296.64M |
| June 30, 2024 | 218.00M |
| March 31, 2024 | 220.25M |
| December 31, 2023 | 229.94M |
| September 30, 2023 | 299.71M |
| June 30, 2023 | 67.84M |
| March 31, 2023 | 466.33M |
| December 31, 2022 | 45.00M |
| September 30, 2022 | 275.29M |
| June 30, 2022 | 139.11M |
| March 31, 2022 | 88.50M |
| December 31, 2021 | 34.60M |
| September 30, 2021 | 92.21M |
| June 30, 2021 | 35.76M |
| March 31, 2021 | 191.92M |
| December 31, 2020 | -95.48M |
| September 30, 2020 | 767.49M |
| Date | Value |
|---|---|
| June 30, 2020 | -6.871M |
| March 31, 2020 | 323.21M |
| December 31, 2019 | 23.14M |
| September 30, 2019 | 49.90M |
| June 30, 2019 | 27.42M |
| March 31, 2019 | 97.13M |
| December 31, 2018 | 31.62M |
| September 30, 2018 | 31.72M |
| June 30, 2018 | 21.23M |
| March 31, 2018 | 76.59M |
| December 31, 2017 | 40.89M |
| September 30, 2017 | 12.88M |
| June 30, 2017 | 80.10M |
| March 31, 2017 | 107.79M |
| December 31, 2016 | -11.74M |
| September 30, 2016 | 30.41M |
| June 30, 2016 | 31.51M |
| March 31, 2016 | -1.276M |
| December 31, 2015 | 37.71M |
| September 30, 2015 | 20.50M |
| June 30, 2015 | -3.258M |
| March 31, 2015 | -8.360M |
| December 31, 2014 | 1.254M |
| September 30, 2014 | 16.71M |
| June 30, 2014 | 9.535M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AbbVie, Inc. | 7.606B |
| Incyte Corp. | -675.32M |
| Ascendis Pharma A/S | 213.77M |
| Zealand Pharma A/S | -26.18M |
| Bavarian Nordic A/S | 138.84M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -9.000M |
| Cash from Financing (Quarterly) | -150.93M |
| Free Cash Flow | 843.28M |
| Free Cash Flow Per Share (Quarterly) | 0.816 |
| Free Cash Flow to Equity (Quarterly) | 584.22M |
| Free Cash Flow to Firm (Quarterly) | 616.34M |
| Free Cash Flow Yield | 2.68% |